Follistatin 344 Certificate of Analysis (COA) Standards
Evaluating a Follistatin 344 COA is a critical baseline step for laboratory researchers requiring standardized biological compounds for in vitro and preclinical study. PX1 Research provides batch-specific documentation verified by independent ISO 17025 accredited laboratories to ensure uncompromising quality control. This guide outlines the essential analytical metrics, testing methodologies, and structural validation standards necessary for verifying Follistatin 344 research material.
Quick answer
Evaluating a Follistatin 344 COA is a critical baseline step for laboratory researchers requiring standardized biological compounds for in vitro and preclinical study. PX1 Research provides batch-specific documentation verified by independent ISO 17025 accredited laboratories to ensure uncompromising quality control. This guide outlines the essential analytical metrics, testing methodologies, and structural validation standards necessary for verifying Follistatin 344 research material.
Key takeaways
- Follistatin 344 is an autocrine glycoprotein expressed across diverse tissue types that functions primarily as a high-affinity binding protein to members of the transforming growth factor-beta (TGF-β) superfamily.
- A comprehensive [Certificate of Analysis](/research-peptides/what-is-a-coa-for-peptides) provides far more than a single purity percentage; it represents a complete chemical profile of the compound.
- High-Performance Liquid Chromatography—specifically Reversed-Phase HPLC (RP-HPLC)—is the gold standard methodology for quantifying the chemical purity of peptide sequences.
- While HPLC confirms chemical homogeneity, Mass Spectrometry (MS) is required to establish unambiguous molecular identity.
Introduction to Follistatin 344 and Quality Assurance
Follistatin 344 is an autocrine glycoprotein expressed across diverse tissue types that functions primarily as a high-affinity binding protein to members of the transforming growth factor-beta (TGF-β) superfamily. In preclinical literature, this peptide sequence is frequently investigated for its ability to neutralize myostatin (GDF-8) and activin A, thereby modulating downstream SMAD signaling pathways within skeletal muscle and cellular models. Because recombinant protein expression and solid-phase peptide synthesis (SPPS) of complex, disulfide-rich molecules can introduce truncated fragments, misfolded isomers, or residual reagents, obtaining a rigorous Follistatin 344 COA is essential before initiating any experimental protocol.
To ensure experimental reproducibility, researchers must verify that every lot of recombinant protein or synthetic peptide conforms to strict identity, purity, and safety benchmarks. A Certificate of Analysis (COA) serves as the official analytical record, detailing the exact molecular metrics of a specific lot. When acquiring materials through the PX1 Research catalog, investigators gain access to fully transparent, lot-tracked documentation verified by independent third-party laboratories operating under ISO 17025 compliance.
Primary Components of a Validated Certificate of Analysis
A comprehensive Certificate of Analysis provides far more than a single purity percentage; it represents a complete chemical profile of the compound. For research peptides, a legitimate COA must outline identity, purity, safety, and physical properties through distinct analytical methodologies. Missing metrics or generalized, non-batch-specific documentation often indicate inadequate quality control processes during synthesis or purification.
When evaluating a COA for Follistatin 344, laboratory staff should verify the presence of five core analytical sections: High-Performance Liquid Chromatography (HPLC) chromatograms, Mass Spectrometry (MS) spectra, bacterial endotoxin assay results, moisture/residual solvent analysis, and physical appearance parameters. Each section must reference specific testing methods, clear acceptance criteria, and lot-matched identification numbers that correlate directly to the vial in the laboratory.
High-Performance Liquid Chromatography (HPLC) Purity Analysis
High-Performance Liquid Chromatography—specifically Reversed-Phase HPLC (RP-HPLC)—is the gold standard methodology for quantifying the chemical purity of peptide sequences. The test separates the target peptide from synthesis side-products, deletion sequences, and oxidized impurities based on hydrophobic interaction with a stationary phase matrix. The resulting chromatogram displays peak area percentages, where the primary peak representing the intact target sequence must account for the vast majority of the total integrated area.
For analytical-grade Follistatin 344, PX1 Research enforces a baseline purity threshold of ≥98.0% as determined by RP-HPLC peak integration. In vitro assays require this high degree of purity to eliminate confounding variables caused by truncated peptide fragments that might bind non-specifically to cell surface receptors. Researchers reviewing the HPLC section of a COA should look for sharp, symmetrical peaks without notable tailing or split peaks, which could indicate structural heterogeneity or degradation.
Mass Spectrometry (MS) for Molecular Identity and Sequence Confirmation
While HPLC confirms chemical homogeneity, Mass Spectrometry (MS) is required to establish unambiguous molecular identity. Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) MS measures the exact mass-to-charge ratio (m/z) of the molecule. This confirms that the observed molecular weight matches the theoretical mass calculated from the primary amino acid sequence of Follistatin 344.
A compliant follistatin 344 coa displays the raw mass spectrum showing the ionized species alongside the calculated theoretical mass. Any significant deviation between expected mass and observed mass indicates sequence errors, incomplete deprotection, or incorrect disulfide bond formation. Confirming exact molecular mass protects researchers against non-functional analogs or mislabeled biological agents during in vitro binding experiments.
Bacterial Endotoxin Quantification and LAL Testing
Endotoxins—lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria—are common contaminants in recombinant expression systems and purified peptide reagents. In cellular biology models, even picogram quantities of endotoxin can trigger inflammatory signaling via Toll-like Receptor 4 (TLR4), confounding observations related to cell proliferation, tissue differentiation, or signaling cascade activation. Consequently, quantification via the Limulus Amebocyte Lysate (LAL) assay is a critical requirement on every lot documentation.
PX1 Research subjects all lot batches to strict endotoxin testing standards, ensuring threshold levels remain below stringent research limits (typically <0.1 EU/μg or <0.05 EU/mg depending on experimental assay parameters). A validated COA must explicitly state the measured endotoxin unit (EU) concentration rather than using ambiguous phrases such as 'pass' or 'low.' This precise data is essential for investigators designing sensitive cell culture or primary tissue assays.
Physical Properties: Appearance, Moisture, and Solubility Parameters
Physical quality indicators provide critical insights into the physical stability and handling characteristics of lyophilized cake. A compliant COA documents visual appearance (typically a white to off-white lyophilized powder or uniform cake), moisture content determined via Karl Fischer titration, and reconstitution solubility behavior. Excess residual moisture in a lyophilized vial accelerates hydrolysis and peptide bond cleavage during storage, drastically reducing shelf-life.
Karl Fischer analysis on a high-grade COA should indicate a moisture content strictly controlled below 5.0% w/w. Furthermore, solubility testing confirms that the lyophilized peptide dissolves rapidly and completely in standard laboratory buffers (such as sterile bacteriostatic water or phosphate-buffered saline) without visible particulate matter, turbid precipitation, or persistent foam formation.
ISO 17025 Accreditation and Third-Party Verification Standards
In-house testing performed solely by the manufacturer carries an inherent risk of bias. To guarantee total analytical integrity, PX1 Research utilizes independent, third-party analytical laboratories that hold ISO/IEC 17025 accreditation. This international standard certifies that the testing laboratory possesses the technical competence, calibrated instrumentation, and validated methodologies necessary to generate precise, unbiased analytical data.
When inspecting a follistatin 344 coa, researchers should verify that the analytical certificate includes the testing laboratory's name, ISO accreditation details, sample identification codes, and official signatures of the quality control manager. Transparency at this level ensures that the analytical findings are fully audit-compliant and reproducible across different research facilities.
Comparative Analysis: Follistatin 344 and Related TGF-β Antagonists
Within preclinical research focused on myostatin inhibition and tissue remodeling, several distinct compounds are evaluated alongside Follistatin 344. Understanding the structural and analytical distinctions between these related molecules helps researchers select the appropriate target and interpret COA data correctly. Prominent compounds in this research class include Follistatin 315, the decoy receptor ACE-031, and broader myostatin antagonists.
While Follistatin 344 represents the precursor peptide that yields serum-circulating isoforms, Follistatin 315 features a modified C-terminal sequence altering tissue-retention characteristics. Similarly, ACE-031 operates via a recombinant fusion protein structure involving the ACVR2B receptor domain, resulting in a significantly larger molecular weight (~110 kDa dimer) compared to the monomeric follistatin peptides (~38 kDa). Consequently, high-performance liquid chromatography and mass spectrometry parameters differ substantially between these agents, requiring targeted assay protocols on their respective COAs.
Laboratory Handling, Reconstitution, and Storage Guidance
Proper handling and storage procedures are paramount to maintain the integrity verified by the COA once the peptide arrives at the research facility. Lyophilized Follistatin 344 should be stored upon arrival at -20°C or -80°C in a manual defrost freezer away from light. Repeated freeze-thaw cycles must be strictly avoided, as thermal fluctuations induce protein aggregation and structural denaturation.
Reconstitution should be performed under aseptic conditions using sterile reconstitution vehicles. Investigators should allow the vial to reach room temperature before adding liquid, gently swirling the container to dissolve the powder completely without vortexing. Once reconstituted, aliquoting into single-use research volumes and freezing at -80°C preserves functional stability for subsequent in vitro assays. Researchers managing large-scale operations can consult our wholesale research accounts division for bulk handling specifications and specialized packaging protocols.
PX1 Research Quality Assurance and Supply Chain Security
PX1 Research is dedicated to supporting scientific advancement by supplying USA-synthesized research peptides manufactured in state-of-the-art, GMP-compliant facilities. Every lot of Follistatin 344 undergoes comprehensive analytical characterization, ensuring that researchers receive fully verified, high-purity biological compounds backed by accessible, batch-specific documentation.
To prevent project delays, PX1 Research operates centralized distribution centers in California and Arizona, offering same-day shipping for orders placed Monday through Friday before cut-off times. By maintaining total transparency, rigorous endotoxin controls, and ISO 17025 accredited testing, PX1 Research stands as a trusted supply partner for institutional laboratories and preclinical researchers nationwide.
Frequently Asked Questions
What is the primary role of Follistatin 344 in preclinical research?
Follistatin 344 is supplied strictly as a research-grade compound for in vitro and laboratory investigation into TGF-β superfamily signaling, specifically focusing on myostatin (GDF-8) and activin neutralization mechanisms.
How can I verify the authenticity of a Follistatin 344 COA from PX1 Research?
Every PX1 Research COA includes a lot-specific tracking number, direct references to third-party ISO 17025 accredited analytical laboratories, and actual HPLC/MS spectral data matching the specific vial received.
What HPLC purity standard is required for research-grade Follistatin 344?
PX1 Research mandates an HPLC purity threshold of ≥98.0% for analytical-grade Follistatin 344 to ensure minimal background noise and interference in sensitive cellular assays.
Why is endotoxin testing critical on a Follistatin 344 COA?
Bacterial endotoxins trigger TLR4 inflammatory pathways in cell cultures, skewing experimental results. A validated COA proves that endotoxin levels are strictly below acceptable thresholds (e.g., <0.1 EU/μg).
What is the difference between Follistatin 344 and Follistatin 315 on a COA?
Follistatin 344 and Follistatin 315 differ in their amino acid sequence length and C-terminal processing, resulting in distinct theoretical molecular weights on mass spectrometry analysis and differing elution profiles on HPLC chromatograms.
How should lyophilized Follistatin 344 be stored upon arrival at the lab?
Lyophilized vials should be stored at -20°C or -80°C in a dry, dark environment. Reconstituted solutions should be aliquoted and maintained at -80°C to avoid activity loss from repeated freeze-thaw cycles.
Where are PX1 Research peptides synthesized and shipped from?
PX1 Research compounds are USA-synthesized in GMP-compliant facilities and shipped directly from distribution hubs in California and Arizona with same-day dispatch available Monday through Friday.
Are PX1 Research peptides intended for human administration?
No. All compounds provided by PX1 Research are strictly for laboratory research, in vitro experiments, and preclinical study. They are explicitly not for human consumption, medical diagnosis, or therapeutic use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.